Abstract: A glass composition having a content of SiO2 that is greater than or equal to about 44.0 mol. % and less than or equal to about 60.0 mol. % and a content of ZnO that is less than or equal to about 1.0 mol. %. Additionally, the glass composition is essentially free of Pb and Bi. The glass composition also has a refractive index that is greater than or equal to 1.75 and a density that is less than or equal to about 4.5 g/cm3.

Abstract: Disclosed herein are glasses that present several advantages over traditional glass compositions used in optical applications. The glasses disclosed herein have a low devitrification tendency and can be processed by melt quenching and formed into macroscopic components. The glasses have high glass thermal stability indices and are chemically durable. The glasses disclosed herein are transparent when heat treated in air or oxygen and have high refractive indices and low density, as well, making them suitable for optical applications.

Abstract: A cash management apparatus includes: a communication interface configured to acquire information of cash stored in a cash handling apparatus and information of cash kept outside the cash handling apparatus; a memory configured to store the information of the cash stored in the cash handling apparatus, and store the information of the cash kept outside the cash handling apparatus as information of cash kept in a virtual safe; and processing circuitry configured to output the information, of the cash kept in the virtual safe, which is stored in the memory, to notify a user. A plurality of pieces of information, each of which is information of cash kept in each of a plurality of virtual safes, is stored in the memory.

Abstract: Foamed thermoplastic vulcanizate compositions having minimal water absorption, and in particular having predominantly closed cell structure. The foam compositions exhibit desirable properties including, but not limited to, low density, tensile strength, ultimate elongation, and low modulus of elasticity. The foam may be used in one or more commercial products or articles, such as use in forming weather seals.

Abstract: In embodiments, a glass composition may include: greater than or equal to 71 mol. % and less than or equal to 83 mol. % SiO2; greater than or equal to 1 mol. % and less than or equal to 11 mol. % Al2O3; greater than or equal to 5 mol. % and less than or equal to 18 mol. % alkali oxide, the alkali oxide comprising greater than 3 mol. % Li2O and at least one of Na2O and K2O; greater than or equal to 1 mol. % and less than or equal to 8 mol. % alkaline earth oxide, the alkaline earth oxide comprising MgO and at least one of CaO, BaO, and SrO; and at least one of TiO2, ZrO2, HfO2, La2O3 and Y2O3, wherein TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than 0 mol. % and less than or equal to 6 mol. % and Al2O3+TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than or equal to 2 mol. % and less than or equal to 12 mol. %.

Abstract: An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

Abstract: Disclosed herein are glasses that present several advantages over traditional glass compositions used in optical applications. The glasses disclosed herein have a low devitrification tendency and can be processed by melt quenching and formed into macroscopic components. The glasses have high glass thermal stability indices and are chemically durable. The glasses disclosed herein are transparent when heat treated in air or oxygen and have high refractive indices and low density, as well, making them suitable for optical applications.

Abstract: A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: A borate glass includes from 25.0 mol % to 70.0 mol % B2O3; from 0.0 mol % to 10.0 mol % SiO2; from 0.0 mol % to 15.0 mol % Al2O3; from 3.0 mol % to 15.0 mol % Nb2O5; from 0.0 mol % to 12.0 mol % alkali metal oxides; from 0.0 mol % to 5.0 mol % ZnO; from 0.0 mol % to 8.0 mol % ZrO2; from 0.0 mol % to 15.0 mol % TiO2; less than 0.5 mol % Bi2O3; and less than 0.5 mol % P2O5. The optical borate glass includes a sum of B2O3+Al2O3+SiO2 from 35.0 mol % to 76.0 mol %, a sum of CaO+MgO from 0.0 mol % to 35.5 mol %. The borate glass has a refractive index, measured at 587.6 nm, of greater than 1.70, a density of less than 4.50 g/cm3, and an Abbe number, VD, from 20.0 to 47.0.

Abstract: An optical boroaluminate glass article comprises: from greater than or equal to 10.0 mol % to less than or equal to 30.0 mol % Al2O3; from greater than or equal to 10.0 mol % to less than or equal to 55.0 mol % CaO; from greater than or equal to 10.0 mol % to less than or equal to 25.0 mol % B2O3; from greater than or equal to 0.0 mol % to less than or equal to 30.0 mol % SiO2; and from greater than or equal to 1.0 mol % to less than or equal to 20.0 mol % refractive index raising components. The optical boroaluminate glass article has a refractive index of the glass article, measured at 589.3 nm, of greater than or equal to 1.62, and a density of less than or equal to 4.00 g/cm3.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

Abstract: An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds.